Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET
Company Participants
Molly Aggas – Account Supervisor, Dalton Agency
A.J. Kazimi – CEO
Todd Anthony – VP, Organizational Development
John Hamm – CFO
Conference Call Participants
Operator
Good afternoon, and welcome to the Cumberland Pharmaceuticals First Quarter 2025 Financial Report and Company Update. This call is being recorded at the company’s request and will be archived on its website for one year from today’s date.
I would now like to turn the call over to Molly Aggas, Account Supervisor at the Dalton Agency who handles Cumberland’s communications.
Molly, please proceed.
Molly Aggas
Hello, everyone and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its first financial results. The release also provided an operational update including key recent developments during the quarter. The release, which includes the related financial tables, can be found on the company’s website at www.cumberlandpharma.com.
Management will share an overview of those financial results during today’s call. They’ll also provide an overall company update, including a discussion of Cumberland’s brands, pipeline, and partners.
Participating in today’s call are A.J. Kazimi, Cumberland’s Chief Executive Officer; Todd Anthony, Vice President, Organizational Development; and John Hamm, Chief Financial Officer.
Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Reform Act. Those statements reflect the company’s current views and expectations concerning future events and may involve risks as well as uncertainties. There are many factors that could affect Cumberland’s future results, including natural disasters, economic downturns, public health epidemics, international conflicts, trade restrictions and others that are beyond the company’s control.
Those issues are described under the caption, Risk Factors, in Cumberland’s Form 10-K and any additional updates filed with the SEC. Any forward-looking
#Cumberland #Pharmaceuticals #CPIX #Earnings #Call #Transcript